Ruiz-Argüelles Guillermo J, Gómez-Almaguer David, Vela-Ojeda Jorge, Morales-Toquero Amelia, Gómez-Rangel Jóse David, García-Ruiz-Esparza Miriam A, López-Martínez Briceida, Cantú-Rodríguez Olga G, Gutiérrez-Aguirrec César H
Centro de Hematología y Medicina Interna de Puebla, Puebla, PUE, Mexico.
Int J Hematol. 2005 Oct;82(3):262-5. doi: 10.1532/IJH97.04195.
Of a group of 149 patients who underwent allogeneic stem cell transplantation using the "Mexican approach", a nonablative preparative regimen, 49 individuals developed bone marrow relapse, and 8 patients developed extramedullary relapse (EMR). All EMR cases presented in patients who received allografts for myeloid malignancies. In contrast, bone marrow relapses presented in patients with myeloid or lymphoid malignancies. EMR presented 60 to 1010 days after the allograft and appeared in 3 cases as subcutaneous nodules in different parts of the body, in the vertebrae in 3 cases, and in the kidney and the breast in 1 case each. One patient had both subcutaneous nodules and epididymis EMR. When EMR was noted, acute graft-versus-host disease (GVHD) had presented in 4 patients, and limited forms of chronic GVHD were present in 3 patients. All but 1 of the patients were full chimeras when the EMR ensued, and the EMR preceded an overt hematologic relapse in all but 1 of the patients. Patients who experienced an overt hematologic relapse died 20 to 180 days (median, 40 days) after the EMR. The only individual alive 240 days after relapse shows no evidence of a full-blown hematologic relapse. An EMR after allogeneic hematopoietic stem cell transplantation usually has a bad prognosis and presents mainly in individuals with high-risk malignancies.
在一组149例采用“墨西哥方法”(一种非清髓性预处理方案)进行异基因干细胞移植的患者中,49例发生骨髓复发,8例发生髓外复发(EMR)。所有EMR病例均出现在接受髓系恶性肿瘤同种异体移植的患者中。相比之下,骨髓复发则出现在髓系或淋巴系恶性肿瘤患者中。EMR发生在移植后60至1010天,3例表现为身体不同部位的皮下结节,3例出现在椎骨,1例出现在肾脏和乳腺。1例患者既有皮下结节又有附睾EMR。发现EMR时,4例患者出现了急性移植物抗宿主病(GVHD),3例患者存在局限性慢性GVHD。除1例患者外,所有患者在发生EMR时均为完全嵌合体,除1例患者外,所有患者的EMR均先于明显的血液学复发。发生明显血液学复发的患者在EMR后20至180天(中位值40天)死亡。复发后240天仍存活的唯一患者没有出现明显血液学复发的迹象。异基因造血干细胞移植后的EMR通常预后不良,主要发生在高危恶性肿瘤患者中。